Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.
Jillian S Y Lau, Deborah Cromer, Mykola Pinkevych, Sharon R Lewin, Thomas A Rasmussen, James H McMahon, Miles P Davenport
Author Information
Jillian S Y Lau: Department of Infectious Diseases, Alfred Hospital, Prahran, Australia. ORCID
Deborah Cromer: Infection Analytics Program, Kirby Institute, University of New South Wales, Sydney, Australia.
Mykola Pinkevych: Infection Analytics Program, Kirby Institute, University of New South Wales, Sydney, Australia.
Sharon R Lewin: Department of Infectious Diseases, Alfred Hospital, Prahran, Australia.
Thomas A Rasmussen: Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
James H McMahon: Department of Infectious Diseases, Alfred Hospital, Prahran, Australia.
Miles P Davenport: Infection Analytics Program, Kirby Institute, University of New South Wales, Sydney, Australia.
BACKGROUND: Analytical treatment interruptions (ATI) are pauses of antiretroviral therapy (ART) in the context of human immunodeficiency virus (HIV) cure trials. They are the gold standard in determining if interventions being tested can achieve sustained virological control in the absence of ART. However, withholding ART comes with risks and discomforts to trial participant. We used mathematical models to explore how ATI study design can be improved to maximize statistical power, while minimizing risks to participants. METHODS: Using previously observed dynamics of time to viral rebound (TVR) post-ATI, we modelled estimates for optimal sample size, frequency, and ATI duration required to detect a significant difference in the TVR between control and intervention groups. Groups were compared using a log-rank test, and analytical and stochastic techniques. RESULTS: In placebo-controlled TVR studies, 120 participants are required in each arm to detect 30% difference in frequency of viral reactivation at 80% power. There was little statistical advantage to measuring viral load more frequently than weekly, or interrupting ART beyond 5 weeks in a TVR study. CONCLUSIONS: Current TVR HIV cure studies are underpowered to detect statistically significant changes in frequency of viral reactivation. Alternate study designs can improve the statistical power of ATI trials.
